Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Elizabeth, Merikle"'
Autor:
Victoria Brown, Elizabeth Merikle, Kelly Johnston, Katherine Gooch, Ivana Audhya, Linda Lowes
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-9 (2023)
Abstract Background Duchenne muscular dystrophy (DMD) is a rare, severe, fatal neuromuscular disease characterized by progressive atrophy and muscle weakness, resulting in loss of ambulation, decreased upper body function, and impaired cardiorespirat
Externí odkaz:
https://doaj.org/article/a3f05c6915a74489a66b33025bf27d4d
Autor:
Elizabeth Berry-Kravis, Randi Hagerman, Dejan Budimirovic, Craig Erickson, Helen Heussler, Nicole Tartaglia, Jonathan Cohen, Flora Tassone, Thomas Dobbins, Elizabeth Merikle, Terri Sebree, Nancy Tich, Joseph M. Palumbo, Stephen O’Quinn
Publikováno v:
Journal of Neurodevelopmental Disorders, Vol 14, Iss 1, Pp 1-15 (2022)
Abstract Background Fragile X syndrome (FXS) is associated with dysregulated endocannabinoid signaling and may therefore respond to cannabidiol therapy. Design CONNECT-FX was a double-blind, randomized phase 3 trial assessing efficacy and safety of Z
Externí odkaz:
https://doaj.org/article/9b2b2328cf084b42bc90fb9b752f13e7
Autor:
Kelly Johnston, Cristina Casstevens, Vanessa Perez Patel, Elizabeth Merikle, Carrie Presnall, Ivana Audhya
Publikováno v:
Advances in Therapy. 40:2296-2310
Autor:
Geneviève Gauthier, Annie Guérin, Maryia Zhdanava, William Jacobson, George Nomikos, Elizabeth Merikle, Clément François, Vanessa Perez
Publikováno v:
BMC Psychiatry, Vol 17, Iss 1, Pp 1-12 (2017)
Abstract Background Although the symptoms of major depressive disorder (MDD) are often manageable with pharmacotherapy, response to first-line antidepressant treatment is often less than optimal. This study describes long-term treatment patterns in M
Externí odkaz:
https://doaj.org/article/5af784861ce7467ca47943fea134e545
Autor:
Albena Patroneva, Amee Revana, Vanessa Perez Patel, Daniel G. Glaze, Elizabeth Merikle, Krystle Davis
Publikováno v:
J Clin Sleep Med
STUDY OBJECTIVES: Excessive daytime sleepiness is common in Prader-Willi syndrome (PWS), with prevalence ranging from 52% to 100%. The goal of this study was to establish the content validity (ie, evidence that an instrument measures an intended conc
Autor:
Shelagh Szabo, Elizabeth Merikle, Greta Lozano-Ortega, Lauren Powell, Thomas Macek, Stephanie Cline
Publikováno v:
Schizophrenia Research and Treatment, Vol 2018 (2018)
Objective. To perform a systematic review of the published literature to evaluate how functional capacity, as measured by the University of California at San Diego (UCSD) Performance-based Skills Assessment (UPSA), relates to other functional measure
Externí odkaz:
https://doaj.org/article/894f679e80da4dd98c9570e423f8ba6a
Autor:
Erika Brockfeld McClure, Elizabeth Merikle, Janice Smiell, James H. Holmes, Tzy-Chyi Yu, Elaine A. Böing, Angela Gibson
Publikováno v:
Burns. 47:1066-1073
Reducing the amount of donor skin needed for definitive wound closure can improve outcomes in patients with severe burns. This Delphi Consensus Panel (DCP) aimed to achieve expert consensus on the percentage reduction in donor skin for autograft that
Autor:
Angela Gibson, James H. Holmes, Tzy-Chyi Yu, Erika Brockfeld McClure, Janice Smiell, Elizabeth Merikle, Elaine A. Böing
Publikováno v:
Burns : journal of the International Society for Burn Injuries. 47(4)
Autor:
Ferenc Martenyi, Scott J. Johnson, Elizabeth Merikle, Matthew Davis, Stephanie Cline, Thomas O`Connell, Kit N. Simpson
Publikováno v:
Current Alzheimer Research. 15:777-788
Background: Alzheimer’s Disease (AD) can be conceptualized as a continuum: patients progress from normal cognition to mild cognitive impairment (MCI) due to AD, followed by increasing severity of AD dementia. Prior research has measured transition
Autor:
Nancy Tich, Elizabeth Merikle, Thomas Dobbins, Stephen O'Quinn, Terri B. Sebree, Joseph Palumbo
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 60:S258
Objectives: ZYN002 is a pharmaceutically manufactured transdermal cannabidiol gel in development for the treatment of behavioral symptoms in Fragile X syndrome (FXS). RECONNECT is a pivotal, randomized, double-blind, Phase 3 trial to assess the effic